Bifogade filer
File
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Dignitana AB (http://www.dignitana.se/), manufacturer of The DigniCap® Scalp Cooling System, has expanded the agreement with oneservice (https://one-service.com/), to provide service and maintenance to European health care facilities offering the DigniCap Delta model of the DigniCap Scalp Cooling System.
As part of Dignitana's ongoing commitment to high-quality customer service, DigniCap Delta customers in Europe can now access the extensive oneservice network for installation, maintenance, technical support and repairs. oneservice, a global provider of specialty technical services, has worked with Dignitana since 2019, previously focusing their efforts on the legacy C3 device. With the introduction of the DigniCap Delta model to Europe, health care providers in Italy, Germany, Spain, Sweden, and The United Kingdom are now utilizing the next generation in scalp cooling technology that is offered with the DigniCap Delta model. As initial warranties expire, these customers can purchase Service Level Agreements from Dignitana which will be administered by oneservice.
"The ability to offer service in the field means European customers now have access to rapid-response service with a high-level of expertise," said Catarina Löwenadler, CEO of Dignitana. "As we work to efficiently to expand DigniCap availability, we know we can rely on the industry experts and state-of-the-art resources at oneservice for consistent, high-quality and excellent service."
"We are proud to expand the scope of our work with Dignitana, servicing a market with enormous potential, while also supporting quality of life for cancer patients," said Matthias Raquet, CEO of oneservice. "We enjoy working with new technologies such as the thermoelectric cooling system in DigniCap Delta that can positively impact the quality of life of patients undergoing chemotherapy and we look forward seeing more customers across Europe adopt this innovative technology."
Löwenadler added, "Excellent customer service is a top priority for Dignitana, where we see 94 percent of DigniCap patients surveyed state they would recommend DigniCap to others, and 75 percent report satisfaction with their DigniCap results. With this expanded oneservice agreement, we continue to do all we can to support the patient's journey with dignity and respect."
Hailed internationally as a life-changing medical advancement for cancer patients, The DigniCap Scalp Cooling System was invented by a Swedish Oncology nurse in 1999 and has been available in Europe since 2001. DigniCap was the first scalp cooling system to be cleared by the US Food and Drug Administration and is used to minimize chemotherapy induced hair loss in patients with solid tumor cancers. The pivotal trial achieved clinically superior results, with 66.3 percent of patients keeping the majority of their hair while undergoing chemotherapy.
There are nearly 3.7 million new cancer diagnoses in Europe per year (WHO (http://www.euro.who.int/en/health-topics/noncommunicable-diseases/cancer/data-and-statistics)) and breast cancer is the most common cancer in European women with approximately 500,000 new diagnoses per year (European Breast Cancer Coalition (https://www.europadonna.org/breast-cancer-facs/)).